vTv Therapeutics Inc
VTVT14.690USD
+0.115+0.79%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
38.37MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über vTv Therapeutics Inc Unternehmen
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
Unternehmensinformationen
BörsenkürzelVTVT
Name des UnternehmensvTv Therapeutics Inc
IPO-datumJul 30, 2015
CEOMr. Paul Jai Sekhri
Anzahl der mitarbeiter23
WertpapierartOrdinary Share
GeschäftsjahresendeJul 30
Addresse3980 Premier Dr
StadtHIGH POINT
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl27265
Telefon13368410300
Websitehttps://vtvtherapeutics.com/
BörsenkürzelVTVT
IPO-datumJul 30, 2015
CEOMr. Paul Jai Sekhri
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-82.80%
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
2.25K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
--
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
Dan Spiegelman
Dan Spiegelman
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-82.80%
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
2.25K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
--
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2023
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
MacAndrews & Forbes Holdings, Inc.
34.88%
Samsara BioCapital, LLC
7.90%
Fidelity Management & Research Company LLC
6.81%
Baker Bros. Advisors LP
3.72%
The Vanguard Group, Inc.
1.59%
Other
45.10%
Aktionäre
Aktionäre
Anteil
MacAndrews & Forbes Holdings, Inc.
34.88%
Samsara BioCapital, LLC
7.90%
Fidelity Management & Research Company LLC
6.81%
Baker Bros. Advisors LP
3.72%
The Vanguard Group, Inc.
1.59%
Other
45.10%
Aktionärstypen
Aktionäre
Anteil
Holding Company
34.88%
Investment Advisor
8.96%
Venture Capital
7.90%
Hedge Fund
4.09%
Investment Advisor/Hedge Fund
1.09%
Individual Investor
0.72%
Other
42.35%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
54
1.51M
57.65%
-16.72K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
2023Q3
72
1.41M
69.35%
-49.61K
2023Q2
81
1.40M
81.32%
+323.67K
2023Q1
107
1.40M
81.41%
+294.71K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
MacAndrews & Forbes Holdings, Inc.
912.98K
34.88%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
206.78K
7.9%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
178.20K
6.81%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
97.31K
3.72%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
41.56K
1.59%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
15.63K
0.6%
+15.63K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
12.64K
0.48%
+1.00K
+8.62%
Mar 31, 2025
Connective Capital Management, LLC
9.38K
0.36%
+9.38K
--
Mar 31, 2025
Sekhri (Paul Jai)
5.00K
0.19%
-24.06K
-82.80%
Apr 01, 2025
Northern Trust Global Investments
4.71K
0.18%
-194.00
-3.96%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Anteil0.01%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Datum
Art
Verhältnis
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
